Precocious puberty treatment sales will strengthen through 2036, anchored by leuprorelin at 42.6% of the drug class segment in 2026. The market was valued at USD 1.99 billion in 2025 and is expected to be worth USD 4.29 billion by 2036, creating an incremental opportunity of USD 2.15 billion.